Please disable your Ad Blocker to better interact with this website.

Mucarsel-Powell, Scott tackle costs of prescription drugs
Featured

Mucarsel-Powell, Scott tackle costs of prescription drugs

485
0
98SHARES

Republicans and Democrats in congress agree on very few things nowadays, so when there is “bipartisanship” to be had on any piece of legislation, it’s a rare occasion that both sides like to highlight.

This is the case for lowering the price on prescription drugs.

Florida Senator Rick Scott (R) has introduced the Transparency Drug Pricing Act, a bill would require drug makers to list all patient costs for prescription drugs.

Trending: Trump’s “Go Back” Tweet Sparks Verbal War

The bill appears to be receiving bipartisan support in the senate, as does Rep. Debbie Mucarsel-Powell (D) co-sponsored Terminating the Extension of Rights Misappropriated (TERM) Act of 2019 in the House, which also addresses the rising costs of prescription drugs, but focuses on tackling the process of “evergreening” drug companies practice.

take our poll - story continues below

Which Democrat Presidential Hopeful Has The Wildest Campaign Promise So Far?

  • Which Democrat Presidential Hopeful Has The Wildest Campaign Promise So Far?  

  • This field is for validation purposes and should be left unchanged.
Completing this poll grants you access to Floridian Press updates free of charge. You may opt out at anytime. You also agree to this site's Privacy Policy and Terms of Use.

“This legislation would address the rising cost of prescription drugs by significantly limiting the process known as “evergreening”, whereby pharmaceutical companies make minor changes to a drug and file for a new patent on those trivial changes in order to extend their exclusivity and maintain high prices.”

“Under existing patent statute, generic drug manufacturers must prove why a new patent should not be granted on existing medication. This process adds significant costs to generic manufacturers and slows the ability of lower cost drugs to be released. The TERM Act shifts that burden of proof to pharmaceutical companies, who would have to reasonably demonstrate why changes to a drug qualify it for a new patent.”- Rep. Mucarsel-Powell (D) press release 

 “Americans are paying too much for prescription medications, and I’ve always been committed to working with anyone — Democrat, Republican, Independent — to lower prescription drug costs,” said Mucarsel-Powell “That’s why I’m proud to introduce the bipartisan TERM Act to take on drug manufacturers’ shady practice of amassing endless patents to prevent more affordable generic medicines from reaching the market and to stop these companies from increasing their profits at the expense of hardworking Americans

98SHARES
Tagged:

Javier Manjarres is a nationally renowned award-winning South Florida-based political journalist owns Diverse New Media, Corp. which publishes Floridianpress.com, Judicialpost.com, shark-tank.com, and Hispolitica.com He enjoys traveling, playing soccer, mixed martial arts, weight-lifting, swimming and biking. He ran as a Republican in the 2018 congressional primary race in Florida's CD 22. Javier is also a political consultant, and has also authored "BROWN PEOPLE," which is a book about Hispanic Politics. Learn more at www.brownpeople.org Email him at [email protected]

omar
donald trumpFeatured
Omar Faces Backlash for “Black Hawk Down” Tweet
One twitter account questioned her words, asking if she was “a United States [...]
Screen Shot 2019-03-29 at 10.43.55 AM
FeaturedFloridaFlorida Politics
Buchanan Calls for Better Retirement Benefits
“It is imperative we provide as many resources as possible to help folks prepare for [...]
Tampa Event
Featured
State backs off measure to cut behavior analysis rates